Bain Life Sciences co-leads $55m series-D for Inflarx

Cormorant Asset Management and RA Capital Management co-led the round, in which numerous unnamed funds and investment managers took part.

The transaction comprised a $30m capital increase and a $25m secondary share purchase. The fresh capital will be used to advance the company's leading drug candidate into the next clinical phase of development.

Inflarx filed documents with the SEC on 13 October to register for an IPO on Nasdaq to raise up to $86m. The stock exchange's news service announced that JP Morgan, Leerink Partners and BMO Capital Markets are joint bookrunners for the deal, but no pricing information has been disclosed.

Previous funding
In March 2009, BM-T, KFW Mittelstandsbank and Affentrager Associates invested in the final tranche of a three-tranche series-A round. Prior to that, venture capital investors provided seed financing in mid-2008. BM-T subsequently led a series-B funding round for the company in July 2014.

Three years later Staidson Hongkong Investment led a $34m series-C financing for Inflarx with participation from new and existing investors.

Company
Headquartered in Jena, Inflarx develops new therapeutics in the field of acute and chronic inflammation. It focuses on the development of monoclonal antibodies for use against life-threatening inflammatory diseases. Its lead drug candidate, IFX-1, is currently in phase-II clinical development. Inflarx was founded in 2007.

People
Inflarx – Niels Riedemann (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Germany
• Venture